Kate Gofman

Predictive Safety in the Era of Artificial Intelligence: Promises, Limits, and the Case for an Enterprise Lifecycle Evidence Ecosystem

Drug safety remains central to patient benefit, as maximizing the value of beneficial therapies requires recognition, appropriate characterization, and effective mitigation of treatment-related adverse drug reactions (ADRs). These challenges, particularly with the advent of artif...